Application of MANF protein in preparation of anti-aging drugs
By using the MANF protein encoded by astrocyte-derived neurotrophic factor gene, the expression levels of p53, p21, and p16 are reduced, and the problem of lack of effective aging treatment in the prior art is solved, and effective relief of aging diseases is achieved and treatment, with broad clinical application prospects.
Patent Information
- Application Number
- CN202410984112.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-12
AI Technical Summary
The existing technology lacks effective aging-specific therapeutic drugs, resulting in minimal therapeutic effects on aging-related diseases and accompanied by adverse reactions. There is no precedent for MANF protein to be used in the field of anti-aging.
The MANF protein encoded by astrocyte-derived neurotrophic factor gene is used to prepare anti-cellular aging drugs. By reducing the expression levels of p53, p21, and p16, it alleviates physiological and pathological aging and treats aging diseases.
Effectively alleviate and treat aging diseases caused by physiological and pathological aging, significantly reduce the expression level of disease, and has broad clinical application prospects and practical value.
Smart Images

Figure CN118924879A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and medicine, and specifically relates to the application of MANF protein in the preparation of anti-aging drugs. Background Art
[0002] Aging is a difficult problem in scientific research. Generally, aging is divided into physiological aging and pathological aging. The production of senescent cells runs through the entire life process and plays a role in a variety of physiological and pathological processes, including embryogenesis, wound healing, host immunity and tumor suppression. At the same time, with the increase of age, the continuous accumulation of senescent cells will also have adverse consequences, such as the decline or even disorder of the physiological functions of tissues and organs. These non-proliferating cells occupy key positions and produce proinflammatory cytokines, which ultimately lead to the occurrence of aging-related diseases. Many diseases can cause unnatural cellular aging. Under pathological conditions, the proportion of senescent cells increases, which is not conducive to prognosis and even further accelerates the progression of the disease.
[0003] In addition, senescent cells have a series of core characteristics, including persistent growth arrest, expression of anti-proliferative molecules, and activation of damage-sensing signaling pathways leading to the expression of many senescence-related transcripts. Senescent cells have characteristic changes in structure and protein expression, such as increased expression levels of p16, p21, and p53 proteins and increased SA-β-galactosidase activity, and senescent cells show changes in cell morphology in vitro.
[0004] At present, there is no ideal specific drug for treating aging clinically. The main treatment mode is to treat the subjective symptoms of various diseases associated with aging symptomatically. While treating the diseases, these drugs also bring adverse reactions to patients. Many aging diseases are irreversible, and the treatment effect is minimal. There is currently no precedent for the application of MANF protein in the field of anti-aging. Summary of the invention
[0005] In view of the deficiencies in the prior art, the present invention provides an application of a MANF protein in the preparation of an anti-aging drug to solve the problems in the background technology.
[0006] The present invention solves the technical problem by adopting the following technical solution:
[0007] The present invention provides an application of MANF protein in preparing anti-aging drugs.
[0008] Furthermore, the MANF protein is encoded by an astrocyte-derived neurotrophic factor gene;
[0009] The anti-aging drug is specifically anti-cell aging.
[0010] Furthermore, the aging includes one or more of physiological aging or pathological aging.
[0011] Furthermore, the cells include one or more of human submandibular gland epithelial cells or 293T cells.
[0012] Furthermore, the physiological aging is aging caused by physiological degeneration occurring after maturity;
[0013] The pathological aging is aging caused by external factors, and the external factors include diseases.
[0014] Furthermore, the disease includes one or more of Sjögren's syndrome or ureteral obstruction.
[0015] The present invention also provides the use of the gene encoding the MANF protein in the preparation of anti-aging drugs.
[0016] Furthermore, the anti-aging drug is specifically anti-cellular aging.
[0017] The present invention also provides the use of biological materials containing MANF protein coding genes in preparing anti-aging drugs.
[0018] Furthermore, the anti-aging drug is specifically anti-cellular aging;
[0019] The biological material includes an expression vector or a host cell.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The present invention creatively provides the use of MANF protein in the preparation of anti-aging drugs, especially anti-cellular aging drugs. MANF protein can effectively reduce the expression levels of p53, p21, and p16 in diseases, that is, it can effectively alleviate physiological aging and pathological aging, and further can effectively alleviate or treat aging diseases caused by physiological aging and pathological aging. At the same time, the present invention has the same anti-aging effect on cells including human submandibular gland cells and 293T cells. Therefore, it has good clinical application prospects for alleviating and treating aging, and can achieve significant social benefits, with a wide range of application scenarios and practical practical value.
[0022] Other outstanding essential features and significant improvements of the present invention compared to the prior art are further described in detail in the embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0024] Figure 1The expression of MANF, p16, p21, and p53 in the control group, IFN-α group, and IFN-α+MANF group in human submandibular gland epithelial cells;
[0025] Figure 2 The expression of MANF, p16, p21, and p53 in the Control group, IFN-α group, and IFN-α+MANF group in 293T cells;
[0026] Figure 3 The expression of MANF, p16, p21, and p53 in the control group, siRNA-MANF group, and IFN-α+siRNA-MANF group in human submandibular gland epithelial cells;
[0027] Figure 4 The expression of MANF, p16, p21, and p53 in the Control group, siRNA-MANF group, and IFN-α+siRNA-MANF group in 293T cells;
[0028] Figure 5 β-galactosidase staining levels in human submandibular gland epithelial cells in the Control group, IFN-α group, IFN-α+MANF group, NC group, siRNA-MANF group, and IFN-α+siRNA-MANF group;
[0029] Figure 6 β-galactosidase staining levels in the Control group, IFN-α group, IFN-α+MANF group, NC group, siRNA-MANF group, and IFN-α+siRNA-MANF group in 293T cells;
[0030] Figure 7 This is a schematic diagram of the expression of MANF, p16, p21, and p53 in the spleen of mice in the normal control group, aging model group, and MANF group in Example 1;
[0031] Figure 8 The expression diagram of MANF, p16, p21 and p53 in the submandibular gland tissue of mice in the normal control group, Sjögren's syndrome model group and MANF group in Example 1;
[0032] Fig. 9 This is a schematic diagram of the expression of MANF, p16, p21, and p53 in the kidney tissues of mice in the normal control group, unilateral ureteral ligation model group, and MANF group in Example 1. DETAILED DESCRIPTION
[0033] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] Example 1
[0035] The present embodiment provides an application of MANF protein in the preparation of anti-aging drugs. In the present embodiment, MANF (mesencephalic astrocyte-derived neurotrophic factor, MANF) protein is a secreted protein, which is encoded by the astrocyte-derived neurotrophic factor gene. The astrocyte-derived neurotrophic factor gene is the gene most sensitive to endoplasmic reticulum stress screened out from 30,000 genes by microarray technology.
[0036] In this embodiment, anti-aging is specifically anti-cell aging, which includes physiological aging and pathological aging. Physiological aging is the physiological degeneration process that occurs after maturity, and pathological aging is the senile changes caused by various external factors, including various diseases.
[0037] The cells used for anti-cell aging in this embodiment include human submandibular gland epithelial cells and 293T cells. MANF protein also delays aging of other cells, which will not be described one by one here.
[0038] In order to verify the effect of the present invention, model mice were used for verification in this embodiment. It should be noted that the model mice in this embodiment include aging model mice, Sjögren's syndrome model mice and unilateral ureteral obstruction model mice, among which the aging model mice simulate physiological aging, and the Sjögren's syndrome model mice and unilateral ureteral obstruction model mice simulate pathological aging.
[0039] Specifically, the animals were C57BL / 6 female mice, weighing 18g±2g, used for the Sjögren's syndrome model; the animals were C57BL / 6 male mice, weighing 18g±2g, used for the unilateral ureteral obstruction model; the animals were C57BL / 6 female mice, weighing 30g±2g, used for the aging model. Purchased from the Experimental Animal Center of Anhui Medical University. The experimental animal production license number is SCXK (Anhui) 2011-002. The experimental process was approved by the Ethics Review Committee of Anhui Medical University. The animals were kept in the laboratory of the Institute of Clinical Pharmacology of Anhui Medical University, with free access to food and water at a temperature of 23±2°C and a humidity of 40% to 70%. After the animals were purchased, the mice were adaptively raised for one week.
[0040] Drugs and reagents include:
[0041] (1) Tiletamine hydrochloride and zolazepam hydrochloride for injection (Zoletil50): 125 mg of tiletamine + 125 mg of zolazepam, 5 mL of sterile water for injection (2020 Foreign Veterinary Drug Certificate No. 06), purchased from Virbac (France), the drug was dissolved in sterile water for injection, and diluted 20 times with normal saline to a concentration of 2.5 mg / mL for intramuscular injection in mice. 60 μL of 2.5 mg / mL was injected intramuscularly in mice weighing 20 g.
[0042] (2) Pilocarpine: purchased from Abcam (USA). White powder, 10 mg was weighed and dissolved in 10 mL of double distilled water to prepare 1 mg / mL. When used, it was diluted to the required concentration (0.025 mg / mL) and injected intraperitoneally (0.125 mg / kg). 100 μL was injected for every 20 g of mouse.
[0043] (3) Universal two-step immunohistochemistry kit (PV-9000): purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd. (China).
[0044] (4) MANF (Mesencephalic astrocyte-derived neurotrophic factor): purchased from Creative Biomart (USA), 100 mg of powder was added to 100 μl of sterile distilled water to prepare a solution with a concentration of 1 mg / mL, and 5 μl was injected into the submandibular gland of a 20 g mouse.
[0045] (5) Anti-β-actin antibody (T0022): purchased from Affinity (USA).
[0046] (6) Anti-ARMET / ARP antibody (ab67271): purchased from Abcam (USA)
[0047] (7) Anti-p16 antibody (), Anti-p21 antibody (), Anti-p53 antibody (): purchased from Proteintech (China)
[0048] (8) β-galactosidase in situ staining kit: purchased from Biotime (China)
[0049] (9) IFN-α (NBP2-26651): Novus Biologicals
[0050] (10) RPMI1640 medium, fetal bovine serum: Biological Industries, USA
[0051] (11) EDTA antigen retrieval solution: China Zhongshan Jinqiao
[0052] (12) Anti-mouse secondary antibody (SA00001-1), anti-rabbit secondary antibody (SA00001-2): Proteintech, USA
[0053] (13) MANF siRNA: Bioengineering
[0054] (14) Bovine serum albumin (BSA), complete Freund's adjuvant, incomplete Freund's adjuvant: Sigma, USA
[0055] (15) Skimmed milk powder: Yili, China
[0056] The main instruments include:
[0057] Multiskan Go full wavelength microplate reader: Thermo Corporation, USA
[0058] -80℃ ultra-low temperature refrigerator: Sanyo;
[0059] RM2135 paraffin slicer: Leica Microsystems, Germany;
[0060] Upright fluorescence microscope: Leica Microsystems, Germany.
[0061] Chemiluminescence imager (Las4000mini): GE, USA
[0062] Electronic balance (YP402N): Shanghai Jingtian Instrument Factory
[0063] In this example, the antigen-induced Sjögren's syndrome model mice were first established and grouped, including:
[0064] (1) Antigen preparation
[0065] Select female C57BL / 6 mice of about 6-8W, sterilize with Sanisol after killing, put on the sterile operating table to dissect the neck, take out the bilateral submandibular gland tissue, separate the excess capsule and connective tissue and weigh. Put it in a mortar, add an appropriate amount of sterile PBS solution at 0.1g / 10mL, grind on ice, and extract submandibular gland tissue protein. After discarding the precipitation, take the supernatant and perform BCA method quantitative protein concentration until it is adjusted to 5mg / mL, add an equal amount of complete Freund's adjuvant (d0, d7) or incomplete Freund's adjuvant (d14) and shake evenly, so that the antigen is adjusted to an emulsifier with a concentration of 2.5mg / mL.
[0066] (2) Antigen injection
[0067] The first sensitization day was designated as day 0 (d0), and submandibular gland antigen was injected into mice by multiple intradermal injections on the back on days 0 and 7, with a total of 0.1 mL injected per mouse. Immunity booster injections were performed in the same manner on day 14.
[0068] (3) Grouping
[0069] At the 6th week after immunization, mice that met the Sjögren's syndrome model were selected and randomly divided into model group, normal control group, and MANF group, with 10 mice in each group. Except for the normal control group and the model group, the other groups began to receive drug treatment from the 7th week, and continued to receive drug treatment for 2 weeks. The mice were killed at the 9th week.
[0070] The indicator detection in this embodiment includes:
[0071] (1) Observation of the general condition, specifically:
[0072] Observe the mice's skin for scratching, damage, and the condition of their lips.
[0073] (2) Saliva volume test, specifically:
[0074] The saliva volume of the two groups of mice was measured separately, and the saliva volume was collected for a total of 10 minutes. Before the measurement, the mice were injected with anesthetics (5 mg / mL of tiletamine hydrochloride and zolazepam hydrochloride, 100 μL each), and the state of stable breathing, disappearance of corneal reflex, and relaxation of limb muscles was used as the standard of complete anesthesia. After that, pilocarpine (0.025 mg / mL, 100 μL each) was injected intraperitoneally, and saliva was collected 5 minutes after the injection, and saliva was collected for a total of 10 minutes. Take a sterile cotton ball of appropriate size and put it into a 1.5 mL sterile EP tube, weigh it and record it as M1. When measuring the amount of saliva, put the cotton ball into the mouse's cheek, take it out after 10 minutes and put it into the EP tube again, weigh it and record it as M2, and the amount of saliva (mg) is the difference between the weight of M2 and M1.
[0075] (3) Immunohistochemistry was used to determine the expression of MANF, p16, p21 and p53 in the submandibular gland tissue of the two groups of mice.
[0076] The result tracking of this embodiment includes:
[0077] (1) General observation results, specifically:
[0078] From the 3rd week after immunization, the mice in the model group began to lick their tongues and scratch their lips, while the mice in the normal control group did not show such obvious symptoms.
[0079] (2) Changes in the amount of saliva of the two groups of mice at different times: specifically, compared with the normal control group, the amount of saliva of the mice in the model group gradually decreased;
[0080] (3) Immunohistochemistry was used to determine the expression of MANF, p16, p21 and p53 in the submandibular gland tissues of the three groups of mice. Specifically, compared with the normal control group, the expression of MANF, p16, p21 and p53 in the model group mice was increased, while the expression of MANF, p16, p21 and p53 in the MANF group mice was decreased.
[0081] In this embodiment, the establishment and grouping of unilateral ureteral ligation mouse model (UUO) include:
[0082] Grouping
[0083] Male C57BL / 6 mice aged about 6-8 weeks were selected and randomly divided into model group, normal control group and MANF group. There were 10 mice in each group. Except for the normal control group, the other groups underwent unilateral ureteral ligation surgery.
[0084] Establishment of unilateral ureteral ligation (UUO) model
[0085] After anesthesia, the mice were placed in the right lateral position, shaved locally, and covered with a perforated towel after routine disinfection. The left side of the back was selected as the subcostal area for incision, and the skin was cut to the retroperitoneum in sequence. The kidney and ureter were freed, and the left ureter was lifted with a tissue forceps to take the middle part, which was clamped with a hemostatic forceps. The ureter was cut after ligating both ends of the tube with silk thread, and then the skin was sutured continuously. Penicillin was injected intramuscularly after the operation, and the animals were given regular diet and drinking water.
[0086] The characteristics of UUO are: progressive tubular atrophy and interstitial fibrosis, tubular and interstitial cell proliferation, and infiltration of renal parenchyma macrophages and monocytes. These changes eventually lead to tubular interstitial fibrosis and tubular atrophy, and the renal parenchyma is replaced by fibrous tissue, while the glomeruli are relatively unaffected, and hypertension or lipid metabolism abnormalities will not occur. After seven days, the kidneys have already shown cellular senescence caused by unilateral ureteral ligation, and the model is successfully established.
[0087] Drug administration
[0088] The drugs were administered starting from the eighth day after ligation for 2 weeks, and the mice were killed on the 4th day.
[0089] The indicator detection in this embodiment includes:
[0090] (1) Immunohistochemistry was used to determine the expression of MANF, p16, p21 and p53 in the submandibular gland tissues of the two groups of mice.
[0091] The result tracking of this embodiment includes:
[0092] (1) Immunohistochemistry was used to determine the expression of MANF, p16, p21, and p53 in the kidney tissues of the three groups of mice. Specifically, compared with the normal control group, the expression of MANF, p16, p21, and p53 in the model group mice was increased, while the expression of MANF, p16, p21, and p53 in the MANF group mice was decreased.
[0093] (2) The UUO mouse model of this example was successfully constructed. Compared with the normal control group, the expression of MANF in the kidney tissue of the UUO model mice was increased.
[0094] In this embodiment, the establishment and grouping of aging model mice include:
[0095] Grouping
[0096] Female C57BL / 6 mice weighing 30 g ± 2 g were selected and randomly divided into a model group and a MANF group, with 10 mice in each group. The model group was killed after continuous drug administration for 2 weeks.
[0097] The indicator detection in this embodiment includes:
[0098] (1) Immunohistochemistry was used to determine the expression of MANF, p16, p21 and p53 in the spleen tissues of the two groups of mice.
[0099] The result tracking of this embodiment includes:
[0100] (1) Immunohistochemistry was used to determine the expression of MANF, p16, p21, and p53 in the spleen tissues of the three groups of mice. Specifically, compared with the normal control group, the expression of MANF, p16, p21, and p53 in the model group mice was increased, while the expression of MANF, p16, p21, and p53 in the MANF group mice was decreased.
[0101] In this example, cell experiments were performed:
[0102] Cell culture and plating:
[0103] (1) Human submandibular gland epithelial cells (HSGECs) were inoculated into a cell culture flask, and 3 mL of 10% 1640 medium was added for culture. The medium was changed every other day.
[0104] (2) When the cells have grown to full size in the culture flask (i.e., in the logarithmic phase), discard the culture medium and rinse twice with 3 ml of L PBS to remove dead cells or cells that are not attached to the wall.
[0105] (3) Add 1 mL of trypsin for digestion and observe under a microscope. When the cells fall off the wall, discard the trypsin, add 1 mL of culture medium and blow the cells, aspirate all into an EP tube, centrifuge at 1200 rpm / 5 min, discard the supernatant and keep the cells;
[0106] (4) Resuspend in 1 mL of culture medium and inoculate in a six-well plate with 1 × 106 cells per well. The cells were divided into control group, IFN-α (10 ng / mL) group, MANF (1 ng / mL) group, and Rapa (200 nM) group;
[0107] (5) After 48 h of culture, the cell morphology was observed under a microscope and the cell proteins of each group were extracted.
[0108] (6) 293T cells were passaged daily, and the rest was the same as HSGECs.
[0109] Cell protein extraction (on ice):
[0110] (1) Discard the culture medium;
[0111] (2) Wash with PBS using a gun and discard the supernatant. Repeat three times.
[0112] (3) Add 120 μl of lysis buffer (phosphatase inhibitor: PMSF: RIPA = 2:1:100) to each well, shake evenly, place on ice for 30 min, and sonicate for 1 min;
[0113] (4) Scrape the cells on ice using a pipette tip;
[0114] (5) Aspirate and place in EP tube, centrifuge at 13000 rpm / 15 min at 4°C;
[0115] (6) Aspirate the supernatant, add protein loading buffer (4:1), quantify using the BCA method, and seal tightly;
[0116] (7) Boil at 100°C for 10 min to denature the protein and store at -20°C.
[0117] Transfection of siRNA-MANF:
[0118] (1) The cells were seeded in a six-well plate according to the above method, with 1×106 cells per well. The cells were divided into a control group, an IFN-α (10 ng / mL) group, and a siRNA-MANF group;
[0119] (2) Prepare transfection reagents: ①1.5 mL centrifuge tube: 200 μL serum-free 1640 + 5 μL transfection reagent GP-Mate, mix gently, and let stand at room temperature for 5 min; ②1.5 mL centrifuge tube: 200 μL serum-free 1640 + 7.5 μL siRNA-MANF reagent, mix gently, and let stand for 5 min;
[0120] (3) Add ① to ② (do not reverse the order), mix gently, and let stand for 20 minutes before transfection;
[0121] (4) While standing, change the medium in the six-well plate. Add 1600 μl of serum-free 1640 and 400 μl of transfection reagent to the siRNA-MANF well and mix well to a final volume of 2 mL.
[0122] (5) After 4-6 hours, change to 10% 1640 medium;
[0123] (6) Extract protein after 48 hours.
[0124] Please refer to Figure 1-9 As shown, combined with the analysis of the above results, it can be clearly seen that:
[0125] The antigen-induced Sjögren's syndrome mouse model, unilateral ureteral ligation model, and aging mouse model of this embodiment were successfully constructed. By comparison with the model group, the MANF group alleviated the aging of the submandibular gland in the Sjögren's syndrome model, the kidney in the unilateral ureteral ligation model, and the spleen in the aging model. In the experiments of human submandibular gland epithelial cells (HSGECs) and 293T cells, by comparison with the model group, MANF can alleviate the aging of the above two cells caused by IFN-α. On this basis, the present invention provides an application of MANF protein for anti-aging of cells and model mice.
[0126] On this basis, the present invention also provides the use of a gene encoding a MANF protein in the preparation of an anti-aging drug, and the use of a biological material containing a MANF protein encoding gene in the preparation of an anti-aging drug, wherein the biological material includes an expression vector or a host cell.
[0127] For those skilled in the art, although the present invention has been described in detail above by means of general description, specific implementation and test, some modifications or improvements may be made to it on the basis of the present invention. It is obvious that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic characteristics of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention.
[0128] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.
Claims
1. Application of MANF protein in the preparation of anti-aging drugs.
2. The use according to claim 1, characterized in that: The MANF protein is encoded by the astrocyte-derived neurotrophic factor gene; The anti-aging drug is specifically an anti-cellular aging drug.
3. The use according to claim 1 or 2, characterized in that: The aging includes one or more of physiological aging or pathological aging.
4. The use according to claim 2, characterized in that: The cells include one or more of human submandibular gland epithelial cells or 293T cells.
5. The use according to claim 3, characterized in that: The physiological aging is the aging caused by physiological degeneration after maturity; The pathological aging is aging caused by external factors, and the external factors include diseases.
6. The use according to claim 5, characterized in that: The disease includes one or more of Sjögren's syndrome or ureteral obstruction.
7. Application of the gene encoding MANF protein in the preparation of anti-aging drugs.
8. The use according to claim 7, characterized in that: The anti-aging drug is specifically an anti-cellular aging drug.
9. Application of biomaterials containing MANF protein encoding gene in the preparation of anti-aging drugs.
10. The use according to claim 9, characterized in that: The anti-aging drug is specifically an anti-cellular aging drug; The biological material includes an expression vector or a host cell.
